PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 15:43:41 05/06/2024 BST | ||
| 5.85 EUR | -11.23% |
|
| Current month | -22.01% | ||
| 1 month | -49.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 5.85 | -11.23% |
| 04/06/24 | 6.59 | -5.86% |
| 03/06/24 | 7 | -17.16% |
| 31/05/24 | 8.45 | -10.77% |
| 30/05/24 | 9.47 | +2.82% |
Real-time Boerse Frankfurt Warrants
Last update June 05, 2024 at 03:43 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8ZVW |
| ISIN | DE000VM8ZVW8 |
| Date issued | 23/01/2024 |
| Strike | 539.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.32 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.02 € |
|---|---|
| Lowest since issue | 5.85 € |
| Spread | 0.04 € |
| Spread % | 0.64% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat
